Company intelligence / Profile preview

ATLATL Innovation Center

Shanghai, Shanghai, Chinaatlatl.center ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

ATLATL does not develop its own therapeutics but provides infrastructure/services that have enabled numerous biotech startups to reach key milestones such as IND filings and preclinical validation. Over $2B RMB raised by client teams in Beijing alone since inception.\nThe center has established partnerships with major pharma companies like Novo Nordisk and Boehringer Ingelheim to support new drug development efforts.

Therapeutic areas: Multiple
Modalities: Gene therapyCell therapySmall moleculeMonoclonal antibodymRNA-based drugsProtein
Industry: Drug Discovery Services

Partnerships

Novo NordiskBoehringer IngelheimMiltenyi Biotec (MITC CGT innovation center)Charles River LabsDanaherA*STAR Singapore

Beyond the preview

Go deeper on ATLATL Innovation Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATLATL Innovation Center.

Explore the full profile